linifanib

Overview

Linifanib is a multi-kinase inhibitor targeting VEGFR and PDGFR. It was evaluated as a frontline therapy for hepatocellular carcinoma (HCC) but failed to demonstrate superiority over sorafenib.

Evidence in the corpus

• Failed as frontline HCC therapy vs sorafenib (phase III): median OS 8.0–8.8 vs 9.9–10.0 months for sorafenib (HR 1.12–1.15); demonstrated inferior efficacy in first-line setting PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.